Coherus Oncology, Inc.

Coherus Oncology, Inc.verified

CHRS

Price:

$1.4

Market Cap:

$171.37M

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, m...[Read more]

Industry

Biotechnology

IPO Date

2014-11-06

Stock Exchange

NASDAQ

Ticker

CHRS

The Enterprise Value as of June 2026 (TTM) for Coherus Oncology, Inc. (CHRS) is 110.51M

According to Coherus Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 110.51M. This represents a change of 34.35% compared to the average of 82.25M of the last 4 quarters.

Coherus Oncology, Inc. (CHRS) Historical Enterprise Value (quarterly & annually)

How has CHRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Coherus Oncology, Inc. over the last ten years is 795.26M. The current 110.51M Enterprise Value has changed 1.29% with respect to the historical average. Over the past ten years (40 quarters), CHRS's Enterprise Value was at its highest in in the June 2019 quarter at 1.64B. The Enterprise Value was at its lowest in in the June 2025 quarter at -90976370.68.

Quarterly (TTM)
Annual

Average

795.26M

Median

861.61M

Minimum

122.38M

Maximum

1.27B

Coherus Oncology, Inc. (CHRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Coherus Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 104.42%

Maximum Annual Enterprise Value = 1.27B

Minimum Annual Increase = -61.73%

Minimum Annual Enterprise Value = 122.38M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025122.38M-59.48%
2024302.00M-56.33%
2023691.51M-32.97%
20221.03B-14.45%
20211.21B7.96%
20201.12B-11.73%
20191.27B104.42%
2018619.10M40.04%
2017442.07M-61.73%
20161.16B66.42%

Coherus Oncology, Inc. (CHRS) Average Enterprise Value

How has CHRS Enterprise Value performed in the past?

The current Enterprise Value of Coherus Oncology, Inc. (CHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

371.97M

5-year avg

670.72M

10-year avg

795.26M

Coherus Oncology, Inc. (CHRS) Enterprise Value vs. Peers

How is CHRS’s Enterprise Value compared to its peers?

Coherus Oncology, Inc.’s Enterprise Value is less than OmniAb, Inc. (260.96M), greater than Invivyd, Inc. (-73325330.00), less than SELLAS Life Sciences Group, Inc. (1.01B), less than Codexis, Inc. (254.06M), less than Avalo Therapeutics, Inc. (144.04M), less than Protalix BioTherapeutics, Inc. (135.16M), less than C4 Therapeutics, Inc. (320.20M), less than Insight Molecular Diagnostics Inc. (125.45M), greater than Sangamo Therapeutics, Inc. (53.89M), less than Protara Therapeutics, Inc. (138.82M),

Build a custom stock screener for Coherus Oncology, Inc. (CHRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coherus Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Coherus Oncology, Inc. (CHRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Coherus Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Coherus Oncology, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Coherus Oncology, Inc. (CHRS)?

What is the 3-year average Enterprise Value for Coherus Oncology, Inc. (CHRS)?

What is the 5-year average Enterprise Value for Coherus Oncology, Inc. (CHRS)?

How does the current Enterprise Value for Coherus Oncology, Inc. (CHRS) compare to its historical average?